Sophia Aguiar Monteiro Borges, Natacha Regina de Moraes Cerchiari, Erick Ohanesian Polli, Ana Carolina Nonato, Felipe Lima Barreto, Alexandre de Oliveira Esteves, Maarten Jacobus Postma, Ana Marli Christovam Sartori, Patrícia Coelho de Soárez
{"title":"Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review.","authors":"Sophia Aguiar Monteiro Borges, Natacha Regina de Moraes Cerchiari, Erick Ohanesian Polli, Ana Carolina Nonato, Felipe Lima Barreto, Alexandre de Oliveira Esteves, Maarten Jacobus Postma, Ana Marli Christovam Sartori, Patrícia Coelho de Soárez","doi":"10.1080/14737167.2025.2498663","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Recently, new technologies have emerged for the prevention of respiratory syncytial virus (RSV) infections. Reliable epidemiological data are essential for accurately assessing the disease burden and informing health economic evaluations (HEE). This review evaluates how HEE of RSV maternal vaccination (MV) estimated the RSV disease burden.</p><p><strong>Methods: </strong>A systematic search was conducted in MEDLINE, SCOPUS, EMBASE, NHS EED, HTA, Tufts CEA Registry, LILACS, and Web of Science for full HEE of RSV MV. Reporting quality was assessed with the CHEERS 2022 checklist, costs were converted to 2024 U.S. dollars, and a descriptive, interpretive synthesis of the data was performed.</p><p><strong>Results: </strong>All 21 included studies were cost-utility analyses, 10 conducted in high-income countries. The HEE utilized a wide range of data sources to build epidemiological estimates, frequently relying on non-local data, particularly for outpatient rates. National data on RSV hospitalization rates were the most commonly available. No study included equity assessments. The maternal vaccine dose price was identified as a critical factor in the strategy's cost-effectiveness.</p><p><strong>Conclusion: </strong>Enhancing local data availability for RSV, by strengthening the respiratory virus surveillance, is crucial to improve the reliability of HEE of RSV prevention strategies and enable more informed and effective policy decisions.</p><p><strong>Registration: </strong>PROSPERO: CRD42024549989.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"863-896"},"PeriodicalIF":1.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2498663","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Recently, new technologies have emerged for the prevention of respiratory syncytial virus (RSV) infections. Reliable epidemiological data are essential for accurately assessing the disease burden and informing health economic evaluations (HEE). This review evaluates how HEE of RSV maternal vaccination (MV) estimated the RSV disease burden.
Methods: A systematic search was conducted in MEDLINE, SCOPUS, EMBASE, NHS EED, HTA, Tufts CEA Registry, LILACS, and Web of Science for full HEE of RSV MV. Reporting quality was assessed with the CHEERS 2022 checklist, costs were converted to 2024 U.S. dollars, and a descriptive, interpretive synthesis of the data was performed.
Results: All 21 included studies were cost-utility analyses, 10 conducted in high-income countries. The HEE utilized a wide range of data sources to build epidemiological estimates, frequently relying on non-local data, particularly for outpatient rates. National data on RSV hospitalization rates were the most commonly available. No study included equity assessments. The maternal vaccine dose price was identified as a critical factor in the strategy's cost-effectiveness.
Conclusion: Enhancing local data availability for RSV, by strengthening the respiratory virus surveillance, is crucial to improve the reliability of HEE of RSV prevention strategies and enable more informed and effective policy decisions.
近年来，呼吸道合胞病毒（RSV）感染的预防出现了新的技术。可靠的流行病学数据对于准确评估疾病负担和为卫生经济评估提供信息至关重要。本综述评估了RSV母亲疫苗接种（MV）的HEE如何估计RSV疾病负担。方法：系统检索MEDLINE、SCOPUS、EMBASE、NHS EED、HTA、Tufts CEA Registry、LILACS和Web of Science中RSV MV的完整HEE。报告质量采用干杯2022清单进行评估，成本转换为2024年美国标准美元，并对数据进行描述性、解释性综合。结果：所有纳入的21项研究均为成本效用分析，其中10项在高收入国家进行。HEE利用广泛的数据来源来建立流行病学估计，经常依赖于非本地数据，特别是门诊率。关于呼吸道合胞病毒住院率的国家数据是最常见的。没有研究包括公平评估。产妇疫苗剂量价格被确定为战略成本效益的一个关键因素。结论：通过加强呼吸道病毒监测，提高当地RSV数据的可获得性，对于提高RSV预防策略HEE的可靠性，实现更明智和有效的政策决策至关重要。注册：普洛斯彼罗：CRD42024549989。
期刊介绍：
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.
The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
